Walleye Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.23M | Buy |
39,500
+35,600
| +913% | +$2.08M | ﹤0.01% | 1642 |
|
|
2025
Q4 | $232K | Buy |
3,900
+1,600
| +70% | +$87.1K | ﹤0.01% | 3321 |
|
|
2025
Q3 | $125K | Sell |
2,300
-2,400
| -51% | -$137K | ﹤0.01% | 3621 |
|
|
2025
Q2 | $258K | Sell |
4,700
-20,600
| -81% | -$1.21M | ﹤0.01% | 3084 |
|
|
2025
Q1 | $1.79M | Buy |
25,300
+9,600
| +61% | +$646K | ﹤0.01% | 1707 |
|
|
2024
Q4 | $1.03M | Sell |
15,700
-8,600
| -35% | -$576K | ﹤0.01% | 2149 |
|
|
2024
Q3 | $1.71M | Sell |
24,300
-3,100
| -11% | -$259K | ﹤0.01% | 1774 |
|
|
2024
Q2 | $2.26M | Buy |
27,400
+16,200
| +145% | +$1.35M | 0.01% | 1538 |
|
|
2024
Q1 | $978K | Sell |
11,200
-5,100
| -31% | -$457K | ﹤0.01% | 2269 |
|
|
2023
Q4 | $1.57M | Buy |
16,300
+1,800
| +12% | +$159K | ﹤0.01% | 2115 |
|
|
2023
Q3 | $1.28M | Sell |
14,500
-30,800
| -68% | -$2.74M | ﹤0.01% | 2157 |
|
|
2023
Q2 | $3.93M | Buy |
45,300
+13,400
| +42% | +$1.26M | 0.01% | 1139 |
|
|
2023
Q1 | $3.1M | Sell |
31,900
-10,100
| -24% | -$1.05M | 0.01% | 1387 |
|
|
2022
Q4 | $4.35M | Buy |
42,000
+4,900
| +13% | +$460K | 0.01% | 1159 |
|
|
2022
Q3 | $3.15M | Buy |
37,100
+26,800
| +260% | +$2.39M | 0.01% | 1351 |
|
|
2022
Q2 | $854K | Sell |
10,300
-5,300
| -34% | -$422K | ﹤0.01% | 2375 |
|
|
2022
Q1 | $1.2M | Buy |
15,600
+12,200
| +359% | +$1.02M | ﹤0.01% | 2067 |
|
|
2021
Q4 | $300K | Sell |
3,400
-26,400
| -89% | -$2.18M | ﹤0.01% | 3478 |
|
|
2021
Q3 | $2.3M | Sell |
29,800
-1,600
| -5% | -$126K | 0.01% | 1499 |
|
|
2021
Q2 | $2.62M | Buy |
31,400
+14,300
| +84% | +$1.13M | 0.01% | 1271 |
|
|
2021
Q1 | $1.29M | Buy |
17,100
+10,300
| +151% | +$841K | 0.01% | 1695 |
|
|
2020
Q4 | $596K | Sell |
6,800
-19,900
| -75% | -$1.58M | ﹤0.01% | 2497 |
|
|
2020
Q3 | $2.03M | Buy |
26,700
+14,300
| +115% | +$1.45M | 0.01% | 1112 |
|
|
2020
Q2 | $1.53M | Buy |
12,400
+1,500
| +14% | +$149K | 0.01% | 1318 |
|
|
2020
Q1 | $921K | Buy |
10,900
+2,800
| +35% | +$241K | 0.01% | 1361 |
|
|
2019
Q4 | $685K | Sell |
8,100
-18,600
| -70% | -$1.4M | ﹤0.01% | 2135 |
|
|
2019
Q3 | $1.8M | Sell |
26,700
-25,700
| -49% | -$1.98M | 0.02% | 1138 |
|
|
2019
Q2 | $4.49M | Buy |
52,400
+33,000
| +170% | +$2.82M | 0.04% | 512 |
|
|
2019
Q1 | $1.72M | Buy |
19,400
+10,100
| +109% | +$936K | 0.01% | 1207 |
|
|
2018
Q4 | $792K | Sell |
9,300
-5,700
| -38% | -$542K | 0.01% | 1978 |
|
|
2018
Q3 | $1.46M | Buy |
15,000
+7,000
| +88% | +$699K | 0.01% | 1674 |
|
|
2018
Q2 | $754K | Buy |
8,000
+4,800
| +150% | +$420K | ﹤0.01% | 2409 |
|
|
2018
Q1 | $259K | Buy |
+3,200
| New | +$275K | ﹤0.01% | 3243 |
|
|
2017
Q4 | – | Sell |
-1,300
| Closed | -$121 | – | 4348 |
|
|
2017
Q3 | $121 | Buy |
1,300
+1,000
| +333% | +$88.4K | ﹤0.01% | 3523 |
|
|
2017
Q2 | $27 | Sell |
300
-1,000
| -77% | -$91K | ﹤0.01% | 4055 |
|
|
2017
Q1 | $114 | Sell |
1,300
-15,100
| -92% | -$1.34M | ﹤0.01% | 3328 |
|
|
2016
Q4 | $1.36M | Hold |
16,400
| – | – | 0.01% | 1274 |
|
|
2016
Q3 | $1.52M | Buy |
16,400
+16,200
| +8,100% | +$1.53M | 0.01% | 1198 |
|
|
2016
Q2 | $16K | Sell |
200
-200
| -50% | -$17K | ﹤0.01% | 4661 |
|
|
2016
Q1 | $33K | Buy |
400
+100
| +33% | +$8.14K | ﹤0.01% | 4147 |
|
|
2015
Q4 | $31K | Sell |
300
-500
| -63% | -$52.2K | ﹤0.01% | 4168 |
|
|
2015
Q3 | $85K | Sell |
800
-200
| -20% | -$26.7K | ﹤0.01% | 3071 |
|
|
2015
Q2 | $137K | Buy |
+1,000
| New | +$124K | ﹤0.01% | 2786 |
|
Other funds holding BMRN
VCM
VPM
Walleye Trading's BMRN Position: Q4 2025 in Review
Walleye Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,407 shares — an estimated $240K sold.
Walleye Trading first reported a position in BMRN in Q2 2015 and held it in 37 quarters. The position peaked at $7.69M in Q2 2024. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Walleye Trading reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Walleye Trading sold 4,407 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $240K.
- Walleye Trading first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 37 quarters.
- Walleye Trading's BioMarin Pharmaceuticals position peaked at $7.69M in Q2 2024.
- 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Walleye Trading's 13F filing for Q4 2025, filed 13 Feb 2026.